ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We observed that co‐treatment with z‐VAD‐fmk (a caspase inhibitor) inhibited the downregulation of BCR‐ABL and the cascade signalling pathways of BCR‐ABL in CML cells following the treatment with b‐AP15 (Figure 3E).